Top ▲
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 335 | 1q23.3 | SLAMF7 | SLAM family member 7 | |
Mouse | 1 | 333 | 1 H3 | Slamf7 | SLAM family member 7 | |
Rat | 1 | 342 | 13q24 | Slamf7 | SLAM family member 7 |
Previous and Unofficial Names |
CRACC | CS1-L | CD2-like receptor-activating cytotoxic cells |
Database Links | |
Alphafold | Q9NQ25 (Hs), Q8BHK6 (Mm) |
CATH/Gene3D | 2.60.40.10 |
ChEMBL Target | CHEMBL3559386 (Hs) |
Ensembl Gene | ENSG00000026751 (Hs), ENSMUSG00000038179 (Mm), ENSRNOG00000023209 (Rn) |
Entrez Gene | 57823 (Hs), 75345 (Mm), 364049 (Rn) |
Human Protein Atlas | ENSG00000026751 (Hs) |
KEGG Gene | hsa:57823 (Hs), mmu:75345 (Mm), rno:364049 (Rn) |
OMIM | 606625 (Hs) |
Pharos | Q9NQ25 (Hs) |
RefSeq Nucleotide | NM_021181 (Hs), NM_144539 (Mm), NM_001191550 (Rn) |
RefSeq Protein | NP_067004 (Hs), NP_653122 (Mm), NP_001178479 (Rn) |
UniProtKB | Q9NQ25 (Hs), Q8BHK6 (Mm) |
Wikipedia | SLAMF7 (Hs) |
Download all structure-activity data for this target as a CSV file
Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
CS1 is a member of the signalling lymphocyte activation molecule (SLAM) receptor family. CS1 is a membrane glycoprotein primarily expressed on plasma cells. Homophilic interaction (i.e. interaction with itself) of CS1 induces B cell proliferation and autocrine cytokine secretion, thus playing a role in various immune functions. CS1 is a validated molecular target for the development of novel immunotherapeutics with the potential to treat MM, a malignant disease of plasma cells which remains incurable despite advances in treatment (such as bortezomib, lenalidomide and immunotherapies in clinical trial). Indeed, a combination therapy containing the anti-CS1 mAb elotuzumab (elotuzumab + lenalidomide + dexamethasone), was FDA approved for MM in 2015. CS1 expression is also elevated in patients with systemic lupus erythematosus (SLE) [1], suggesting that this condition may also benefit from clinical CS1-targeted inhibition. |
Cell Type Associations | ||||
|
||||
|
||||
|
||||
|
||||
|
Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
General Comments |
This protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590. |
1. Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. (2010) Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol, 160 (3): 348-58. [PMID:20345977]
2. Williams M, Tso JY, Landolfi NF, Powers DB, Liu G. (2010) Therapeutic use of anti-CS1 antibodies. Patent number: US7709610. Assignee: Facet Biotech Corporation. Priority date: 28/05/2003. Publication date: 04/05/2010.
CD molecules: CS1 (CD319). Last modified on 07/08/2019. Accessed on 11/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2850.